Intranasal drugs are an important part of migraine treatment. Migraine headache attacks are prevented by using these medicines. It assists in reducing headache pain and other symptoms like sensitivity to sound or light. Timely treatment enables a patient to get back to their normal routine shortly and may lessen your requirement for different pain medications. Migraine occurrences are not be prevented by this medication. New product launches by key manufacturers, rising R&D activities, and quick drug approvals by regulatory bodies such as the U.S. Food and Drug Administration for chronic and acute migraines have anticipated providing profitable opportunities in the coming years.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
- Aegis Therapeutics LLC
- Neuro Pharma
- Dr. Reddyโs Laboratories
- Novartis AG
- Pfizer Inc.
- Lockhart ltd
- Roche
- Sanofi
- Merck
- Baxter International Inc.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/13025
๐๐๐ ๐
๐๐๐๐๐๐๐ ๐๐
๐๐๐ ๐๐๐๐๐
- This study presents the analytical depiction of the intranasal migraine drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the intranasal migraine drugs market share.
- The current market is quantitatively analyzed from 2021 to 2030 to highlight the intranasal migraine drugs market growth scenario.
- Porterโs five forces analysis illustrates the potency of buyers & suppliers in the intranasal migraine drugs market.
- The report provides a detailed intranasal migraine drugs market analysis based on competitive intensity and how the competition will take shape in coming years
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/13025
In January 2021, Impel Neuro Pharma received U.S. Food and Drug Administration (FDA) approval for the new drug application for INP104, for the acute treatment of migraine headaches.
In March 2021, Cipla received U.S FDA approval to treat migraine attacks for a nasal spray.
In June 2020, Tonix Pharmaceuticals acquired pain and non-addictive migraine treatment programs of Trigemina Inc. and will also acquire the license of TNX-1900 intranasal oxytocin. It has the potential to treat craniofacial pain and migraine.
In January 2019, Dr. Reddy’s Laboratories received the US Food and Drug Administration (FDA) approval for a sumatriptan nasal splash to provide the intense therapy for headache.
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com